CLASS II Drug recall · Reported 14 Sep 2022 · FDA Enforcement Report

Difluprednate Ophthalmic Emulsion recalled by CIPLA

Cipla is recalling Difluprednate Ophthalmic Emulsion, 0.05%, distributed nationwide in the US. The recall was initiated on 22 Aug 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: DEG1HC2, DEG2HC2, DEG3HC2, DEG4HC2, DEG5HC2, DEG6HC2, Exp 01/2023; DEG1IC2, DEG2IC2, DEG3IC2, DEG4IC2, Exp 02/2023; DEG1LC2, DEG2LC2, Exp 05/2023; DEG1BD2, DEG2BD2, DEG3BD2, Exp 07/2023
NDC69097-341
Quantity recalled117,844 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1499-2022
FDA event ID
90796
Recalling firm
Cipla, Warren, NJ
Manufacturer
Cipla USA Inc.
Classification
Class II
Status
Terminated
Recall initiated
22 Aug 2022
FDA classified
7 Sep 2022
Reported
14 Sep 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Eye Drops

Timeline

22 Aug 2022Recall initiated by company
7 Sep 2022Classified by FDA+16 days
14 Sep 2022Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Difluprednate Ophthalmic Emulsion, 0.05%, 5 mL bottle, RX only, Manufactured by Cipla Ltd., India, Manufactured for: Cipla USA, Inc., NJ 07059, NDC 69097-341-35.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

Which lots are affected?

Lot #: DEG1HC2, DEG2HC2, DEG3HC2, DEG4HC2, DEG5HC2, DEG6HC2, Exp 01/2023; DEG1IC2, DEG2IC2, DEG3IC2, DEG4IC2, Exp 02/2023; DEG1LC2, DEG2LC2, Exp 05/2023; DEG1BD2, DEG2BD2, DEG3BD2, Exp 07/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

Other products in this recall event

1 other product · FDA event 90796

This product is part of a recall event; the main page for the event is Difluprednate Ophthalmic Emulsion recalled by CIPLA.

ReportedClassRecallCompanyReasonWhere
CLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLACiplaSterilityNationwide

More recalls from Cipla

All 14

Other Difluprednate recalls

All 4
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLACiplaSterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCiplaSterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCiplaSterilityNationwide